Several clinical trials of the Plk1 inhibitor BI 2536 have been performed in different tumor types [38,39,110,118] and the mono-therapy of Plk1 inhibitors has shown modest efficacy [38,39,111], suggestive of combined strategy. Here, PLK1 is linked to neoplasm.